Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2016 Jun 9

PMID 27270281

Citations 31

Authors

Eva Germovsek

Alison Kent

Tuuli Metsvaht

Irja Lutsar

Nigel Klein

Mark A Turner

Mike Sharland

Elisabet I Nielsen

Paul T Heath

Joseph F Standing

Affiliations

Soon will be listed here.

Abstract

Trough gentamicin therapeutic drug monitoring (TDM) is time-consuming, disruptive to neonatal clinical care, and a patient safety issue. Bayesian models could allow TDM to be performed opportunistically at the time of routine blood tests. This study aimed to develop and prospectively evaluate a new gentamicin model and a novel Bayesian computer tool (neoGent) for TDM use in neonatal intensive care. We also evaluated model performance for predicting peak concentrations and the area under the concentration-time curve from time 0 h to time t h (AUC0- t). A pharmacokinetic meta-analysis was performed on pooled data from three studies (1,325 concentrations from 205 patients). A 3-compartment model was used with the following covariates: allometric weight scaling, postmenstrual and postnatal age, and serum creatinine concentration. Final parameter estimates (standard errors) were as follows: clearance, 6.2 (0.3) liters/h/70 kg of body weight; central volume (V), 26.5 (0.6) liters/70 kg; intercompartmental disposition (Q), 2.2 (0.3) liters/h/70 kg; peripheral volume V2, 21.2 (1.5) liters/70 kg; intercompartmental disposition (Q2), 0.3 (0.05) liters/h/70 kg; peripheral volume V3, 148 (52.0) liters/70 kg. The model's ability to predict trough concentrations from an opportunistic sample was evaluated in a prospective observational cohort study that included data from 163 patients and 483 concentrations collected in five hospitals. Unbiased trough predictions were obtained; the median (95% confidence interval [CI]) prediction error was 0.0004 (-1.07, 0.84) mg/liter. Results also showed that peaks and AUC0- t values could be predicted (from one randomly selected sample) with little bias but relative imprecision, with median (95% CI) prediction errors being 0.16 (-4.76, 5.01) mg/liter and 10.8 (-24.9, 62.2) mg · h/liter, respectively. neoGent was implemented in R/NONMEM and in the freely available TDMx software.

Citing Articles

A Quantitative Examination and Comparison of the Ability of Australian Gentamicin Dosing Guidelines to Achieve Target Therapeutic Concentrations in Neonates.

Grzeskowiak L, Wynne S, Stark M Antibiotics (Basel). 2025; 14(1).

PMID: 39858334 PMC: 11759765. DOI: 10.3390/antibiotics14010048.

A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.

Albanell-Fernandez M, Rodriguez-Reyes M, Bastida C, Soy D Clin Pharmacokinet. 2025; 64(1):1-25.

PMID: 39821208 PMC: 11762427. DOI: 10.1007/s40262-024-01459-z.

Confirming the Suitability of a Gentamicin Dosing Strategy in Neonates Using the Population Pharmacokinetic Approach with Truncated Sampling Duration.

Singu B, Verbeeck R, Pieper C, Ette E Children (Basel). 2024; 11(8).

PMID: 39201833 PMC: 11352679. DOI: 10.3390/children11080898.

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.

Readman J, Acman M, Hamawandi A, Chiu C, Sharland M, Lindsay J J Antimicrob Chemother. 2023; 78(8):1882-1890.

PMID: 37283195 PMC: 10393883. DOI: 10.1093/jac/dkad177.

Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children.

Hollander E, Tuinen E, Scholvinck E, Bergman K, Bourgonje A, Gracchi V Antibiotics (Basel). 2023; 12(5).

PMID: 37237713 PMC: 10215193. DOI: 10.3390/antibiotics12050810.

References

Burton M, Brater D, Chen P, Day R, HUBER P, Vasko M . A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985; 37(3):349-57. DOI: 10.1038/clpt.1985.51. View

Boyle E, Brookes I, Nye K, Watkinson M, Riordan F . "Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens. BMC Pediatr. 2006; 6:8. PMC: 1440860. DOI: 10.1186/1471-2431-6-8. View

Rastogi A, Agarwal G, Pyati S, Pildes R . Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J. 2002; 21(3):234-40. DOI: 10.1097/00006454-200203000-00014. View

Lopez S, Mulla H, Durward A, Tibby S . Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med. 2009; 11(2):267-74. DOI: 10.1097/PCC.0b013e3181b80693. View

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

Turner M, Lewis S, Hawcutt D, Field D . Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr. 2009; 9:50. PMC: 2734345. DOI: 10.1186/1471-2431-9-50. View

Dersch-Mills D, Akierman A, Alshaikh B, Yusuf K . Validation of a dosage individualization table for extended-interval gentamicin in neonates. Ann Pharmacother. 2012; 46(7-8):935-42. DOI: 10.1345/aph.1R029. View

Anderson B, Holford N . Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009; 24(1):25-36. DOI: 10.2133/dmpk.24.25. View

Valitalo P, van den Anker J, Allegaert K, de Cock R, de Hoog M, Simons S . Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. J Antimicrob Chemother. 2015; 70(7):2074-7. PMC: 4472325. DOI: 10.1093/jac/dkv052. View

10.

Ali A, Farouq M, Al-Faify K . Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life. Indian J Pharmacol. 2012; 44(1):36-40. PMC: 3271536. DOI: 10.4103/0253-7613.91864. View

11.

Pacifici G . Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol. 2008; 65(4):419-27. DOI: 10.1007/s00228-008-0599-y. View

12.

Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P . Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol. 2006; 21(7):931-8. DOI: 10.1007/s00467-006-0118-2. View

13.

Lingvall M, Reith D, Broadbent R . The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol. 2004; 59(1):54-61. PMC: 1884965. DOI: 10.1111/j.1365-2125.2005.02260.x. View

14.

Cantey J, Wozniak P, Sanchez P . Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study. Pediatr Infect Dis J. 2014; 34(3):267-72. DOI: 10.1097/INF.0000000000000542. View

15.

Stickland M, Kirkpatrick C, Begg E, Duffull S, Oddie S, Darlow B . An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother. 2001; 48(6):887-93. DOI: 10.1093/jac/48.6.887. View

16.

Heimann G . Renal toxicity of aminoglycosides in the neonatal period. Pediatr Pharmacol (New York). 1983; 3(3-4):251-7. View

17.

Begg E, Barclay M, Kirkpatrick C . The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001; 52 Suppl 1:35S-43S. PMC: 2014626. DOI: 10.1046/j.1365-2125.2001.0520s1035.x. View

18.

Wicha S, Kees M, Solms A, Minichmayr I, Kratzer A, Kloft C . TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. Int J Antimicrob Agents. 2015; 45(4):442-4. DOI: 10.1016/j.ijantimicag.2014.12.010. View

19.

Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View

20.

Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N . Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J Clin Pharmacol. 2014; 78(5):1090-101. PMC: 4243884. DOI: 10.1111/bcp.12444. View